Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001

Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma

Phase 2 bridge data show consistent outcomes in patients with impaired kidney function

Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic

Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial

Parsortix platform to support minimally invasive analysis across various cancer trials

Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment

Belfast base will expand regulatory support, boost innovation and deepen engagement

Responders achieved weight loss and improvements in physical function